Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Erasca, Inc. for allegedly making false and misleading statements related to its cancer drug ERAS-0015. The lawsuit claims Erasca's preclinical data was improperly compared to a competitor and that the company faced patent infringement and trade secret misappropriation allegations from Revolution Medicines. Following these disclosures, Erasca's stock price dropped nearly 48%. Investors who bought Erasca shares between January 14, 2025 and April 26, 2026 and suffered losses are encouraged to contact the law firm by August 10, 2026 to discuss their legal rights.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
